CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer (Q28473504)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer	scientific article

Statements

scholarly article

0 references

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer (English)

0 references

Per Eystein Lønning

13

object named as

Per Eystein Lønning

0 references

Stian Knappskog

2

object named as

Stian Knappskog

0 references

Steinar Lundgren

6

object named as

Steinar Lundgren

0 references

Ingvil Mjaaland

9

object named as

Ingvil Mjaaland

0 references

Ranjan Chrisanthar

1

object named as

Ranjan Chrisanthar

0 references

4

object named as

Gun Anker

0 references

3

object named as

Erik Løkkevik

0 references

Johan Richard Lillehaug

12

object named as

Johan Richard Lillehaug

0 references

author name string

Bjørn Østenstad

5

0 references

Elisabet O Berge

7

0 references

Terje Risberg

8

0 references

Lovise Maehle

10

0 references

Lars Fredrik Engebretsen

11

0 references

language of work or name

0 references

publication date

26 August 2008

0 references

0 references

3

0 references

8

0 references

e3062

0 references

copyright license

Creative Commons Attribution 4.0 International

26 August 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Chk2 activates E2F-1 in response to DNA damage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

ATM and ATR: networking cellular responses to DNA damage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

DNA damage-induced activation of p53 by the checkpoint kinase Chk2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

19 March 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

7 April 2017

Live or let die: the cell's response to p53

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

7 April 2017

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

7 April 2017

hAda3 regulates p14ARF-induced p53 acetylation and senescence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Breast cancer prognostication and prediction in the postgenomic era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Regulation of the p53 transcriptional activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Genomics in breast cancer-therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Transcription-independent pro-apoptotic functions of p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

p53's believe it or not: lessons on transcription-independent death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Study of suboptimum treatment response: lessons from breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Germline TP53 mutations and Li-Fraumeni syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Chemotherapy response and resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Analysis of CHK2 in vulval neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

CHK2 kinase--a busy messenger.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

The INK4A/ARF locus and its two gene products

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Assessment of response to therapy in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

29 September 2017

Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

2 June 2018

p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

2 June 2018

Characterization of tumor-associated Chk2 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

2 June 2018

Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

2 June 2018

p14ARF links the tumour suppressors RB and p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

20 June 2018

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

The Chk2 tumor suppressor is not required for p53 responses in human cancer cells

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Alternative splicing and mutation status of CHEK2 in stage III breast cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

p53 must be competent for transcriptional regulation to suppress tumor formation

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Chk2 regulates transcription-independent p53-mediated apoptosis in response to DNA damage.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Concomitant inactivation of p53 and Chk2 in breast cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Is CHEK2 a cause of the Li Fraumeni syndrome?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

Tumour biology: Policing of oncogene activity by p53

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0003062

21 January 2018

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

27 November 2018

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518116

27 November 2018

Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased risk of breast cancer associated with CHEK2*1100delC

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18725978

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0003062

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2008PLoSO...3.3062C

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28473504&oldid=2120162629"